With international corporate M&A and private equity being the hallmark of the firm, William Fry LLP displays an impressive roster of clients in the sector, working with some of the world’s largest corporates. Spearheaded by M&A heavyweight Ivor Banim, the London office advises on complex transactional work, regularly working in conjunction with the firm’s offices in Cork and Dublin. The firm also displays expertise in real estate, particularly in the retail and leisure sector, as well as in public sector work; the firm is often found advising the State on high-value, multijurisdictional issues. Other key figures include Brian Butterwick, rated by clients as a ‘very solid operator‘, and Aisling O’Gorman, noted for her expertise in renewable energy work, and wind power in particular.
Irish firms in London in London
William Fry LLP
Responsables de la pratique:
Ivor Banim
Autres avocats clés:
Brian Butterwick; Lorena Dunne; Aisling O’Gorman
Les références
‘Complete experts in Irish law coupled with responsiveness and excellent client service.’
‘Brian Butterwick is a very solid operator – knowledgeable, responsive and just generally easy to work with.’
Principaux clients
Amgen
SoftBank
AIB
Tesco
DCC plc
Edwards Lifesciences plc
Glanbia
York Capital Management
Lazard Asset Management
Mayfair Equity Partners
Value Retail
Phoenix Group
Barclays Bank plc
Uniphar plc
U and I Group PLC (formerly Development Securities plc)
Sands Capital
Davy Group
Goodbody
RBC Capital Markets
Yew Grove REIT
Pollen Street Capital
Towerbrook Capital
August Equity Partners
Gresham House Asset Management
Medivet Group
Clayton Dubilier & Rice
New Mountain Capital
Aceto Group
Wealth at Work Group
Kyndryl Group
Nordic Aviation
Mercer
Amarenco Solar
Copenhagen Infrastructure Partners
UKG Group
Principaux dossiers
- Advised UKG Inc. the United States based software-computer company on the acquisition of Immedis Limited and its subsidiaries for a reported €575 million.
- Advised Amgen, one of the world’s leading independent biotechnology companies, on its acquisition of Horizon Therapeutics plc, a global biotechnology company headquartered in Dublin, for an enterprise value of $28.3 billion.
- Advised the Irish Department of Finance on (i) the sale by the State of approximately 10% of AIB Group plc by way of two separate accelerated book built placings, raising gross proceeds of approximately €995m; and (ii) on the sale of 5% of permanentTSB by way of an accelerated book-built placing to institutional investors.